Systematic Financial Management’s Alexion Pharmaceuticals ALXN Stock Holding History

Systematic Financial Management’s Portfolio ALXN Stock Details ALXN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-35	Closed	-$5K	–	252
2020 Q4	$5K	Sell	35 -78	-69%	-$10K	﹤0.01%	242
2020 Q3	$13K	Hold	113	–	–	﹤0.01%	228
2020 Q2	$13K	Hold	113	–	–	﹤0.01%	490
2020 Q1	$10K	Hold	113	–	–	﹤0.01%	468
2019 Q4	$12K	Sell	113 -312	-73%	-$33.4K	﹤0.01%	481
2019 Q3	$42K	Sell	425 -28,633	-99%	-$3.23M	﹤0.01%	498
2019 Q2	$3.81M	Sell	29,058 -33,299	-53%	-$4.29M	0.15%	148
2019 Q1	$8.43M	Sell	62,357 -65,551	-51%	-$8.15M	0.29%	121
2018 Q4	$12.5M	Buy	127,908 +12,173	+11%	+$1.44M	0.38%	94
2018 Q3	$16.1M	Buy	115,735 +63,584	+122%	+$7.98M	0.39%	85
2018 Q2	$6.47M	Buy	+52,151	New	+$6.09M	0.16%	198

Other funds holding ALXN

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return

PCM

Pentwater Capital Management Naples, Florida $16.4B AUM 55.44% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

DKCM

Davidson Kempner Capital Management New York $8.42B AUM 61.81% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Systematic Financial Management's ALXN Position: Q1 2021 in Review

Systematic Financial Management sold out of Alexion Pharmaceuticals (ALXN) in Q1 2021, closing a stake of 35 shares — an estimated $5K sold.

Systematic Financial Management first reported a position in ALXN in Q2 2018 and held it in 11 quarters. The position peaked at $16.1M in Q3 2018. 754 funds tracked by Wall St. Rank hold ALXN as of Q1 2021.

Systematic Financial Management reported no remaining Alexion Pharmaceuticals position as of Q1 2021 after selling out during the quarter.
Systematic Financial Management sold 35 Alexion Pharmaceuticals shares in Q1 2021, an estimated $5K.
Systematic Financial Management first reported a position in Alexion Pharmaceuticals in Q2 2018 and held it in 11 quarters.
Systematic Financial Management's Alexion Pharmaceuticals position peaked at $16.1M in Q3 2018.
754 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q1 2021.

Based on Systematic Financial Management's 13F filing for Q1 2021, filed 10 May 2021.